Hims & Hers Health (HIMS) Non-Current Deferred Tax Liability (2025 - 2026)
Hims & Hers Health (HIMS) reported Non-Current Deferred Tax Liability of $23.5 million for Q1 2026, down 18.52% sequentially from $28.9 million in Q4 2025.
Hims & Hers Health (HIMS) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $23.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $23.5 million; the trailing twelve-month figure through Mar 2026 stood at $23.5 million (changed N/A YoY), and the FY2025 full-year result was $28.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability retreated to $23.5 million in Q1 2026, from $28.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $31.2 million in Q3 2025 to a low of $23.5 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.51 Mn |
| Mar 31, 2026 | 23.51 Mn |
| Dec 31, 2025 | 28.86 Mn |
| Dec 31, 2025 | 28.86 Mn |
| Sep 30, 2025 | 31.21 Mn |
| Sep 30, 2025 | 31.21 Mn |